As of 2025-05-18, the EV/EBITDA ratio of Tianda Pharmaceuticals Ltd (455.HK) is -7.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 455.HK's latest enterprise value is 375.01 mil HKD. 455.HK's TTM EBITDA according to its financial statements is -51.03 mil HKD. Dividing these 2 quantities gives us the above 455.HK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.1x - 7.1x | 5.7x |
| Forward P/E multiples | 4.0x - 5.5x | 4.5x |
| Fair Price | (0.12) - 0.05 | (0.06) |
| Upside | -175.3% - -69.7% | -138.7% |
| Date | EV/EBITDA |
| 2025-04-30 | -7.27 |
| 2025-04-29 | -7.27 |
| 2025-04-28 | -8.40 |
| 2025-04-25 | -8.40 |
| 2025-04-24 | -8.82 |
| 2025-04-23 | -8.70 |
| 2025-04-22 | -8.40 |
| 2025-04-17 | -7.48 |
| 2025-04-16 | -6.55 |
| 2025-04-15 | -6.55 |
| 2025-04-14 | -6.55 |
| 2025-04-11 | -6.55 |
| 2025-04-10 | -6.55 |
| 2025-04-09 | -7.35 |
| 2025-04-08 | -7.90 |
| 2025-04-07 | -7.90 |
| 2025-04-03 | -7.90 |
| 2025-04-02 | -7.90 |
| 2025-04-01 | -8.40 |
| 2025-03-31 | -8.40 |
| 2025-03-28 | -8.40 |
| 2025-03-27 | -8.57 |
| 2025-03-26 | -8.57 |
| 2025-03-25 | -8.57 |
| 2025-03-24 | -7.90 |
| 2025-03-21 | -8.40 |
| 2025-03-20 | -8.57 |
| 2025-03-19 | -8.40 |
| 2025-03-18 | -8.23 |
| 2025-03-17 | -7.90 |
| 2025-03-14 | -7.90 |
| 2025-03-13 | -7.81 |
| 2025-03-12 | -7.81 |
| 2025-03-11 | -7.81 |
| 2025-03-10 | -7.81 |
| 2025-03-07 | -8.40 |
| 2025-03-06 | -8.40 |
| 2025-03-05 | -7.94 |
| 2025-03-04 | -7.94 |
| 2025-03-03 | -7.64 |
| 2025-02-28 | -7.98 |
| 2025-02-27 | -7.98 |
| 2025-02-26 | -7.98 |
| 2025-02-25 | -7.98 |
| 2025-02-24 | -7.98 |
| 2025-02-21 | -8.61 |
| 2025-02-20 | -8.61 |
| 2025-02-19 | -8.61 |
| 2025-02-18 | -8.61 |
| 2025-02-17 | -8.61 |